Century Therapeutics, Inc.
IPSC
$1.92
-$0.01-0.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 109.16M | 113.34M | 114.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 109.16M | 113.34M | 114.13M |
| Cost of Revenue | 78.92M | 86.19M | 95.66M | 105.34M | 110.04M |
| Gross Profit | -78.92M | -86.19M | 13.50M | 8.00M | 4.09M |
| SG&A Expenses | 28.83M | 28.91M | 29.16M | 31.29M | 32.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.75M | 115.10M | 124.82M | 136.63M | 142.85M |
| Operating Income | -107.75M | -115.10M | -15.66M | -23.29M | -28.72M |
| Income Before Tax | -109.86M | -107.85M | -9.64M | -24.70M | -21.51M |
| Income Tax Expenses | -68.00K | -68.00K | -68.00K | 1.78M | 1.77M |
| Earnings from Continuing Operations | -109.79 | -107.78 | -9.57 | -26.48 | -23.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.79M | -107.78M | -9.57M | -26.48M | -23.28M |
| EBIT | -107.75M | -115.10M | -15.66M | -23.29M | -28.72M |
| EBITDA | -95.46M | -102.21M | -2.56M | -10.42M | -15.68M |
| EPS Basic | -0.90 | -1.11 | -0.11 | -0.31 | -0.28 |
| Normalized Basic EPS | -0.53 | -0.68 | -0.05 | -0.10 | -0.13 |
| EPS Diluted | -0.90 | -1.11 | -0.11 | -0.32 | -0.29 |
| Normalized Diluted EPS | -0.53 | -0.68 | -0.05 | -0.10 | -0.13 |
| Average Basic Shares Outstanding | 573.00M | 453.46M | 346.01M | 344.14M | 342.38M |
| Average Diluted Shares Outstanding | 573.00M | 453.46M | 346.09M | 344.21M | 342.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |